What age is indicated for administering montelukast for exercise-induced bronchoconstriction?

Montelukast is a medication used to prevent exercise-induced bronchoconstriction and is indicated for use in children starting from the age of 6 years. This age is significant because clinical studies have demonstrated its effectiveness and safety in this age group. The underlying reason for establishing the minimum age at which montelukast can be prescribed is based on both the maturation of the respiratory system and the need for a developed understanding of the child's asthma triggers and symptoms.

As children grow, their ability to communicate and recognize symptoms also improves, allowing for more accurate assessments of the medication's effectiveness and any side effects. While montelukast has formulations available for younger children, its specific approval for exercise-induced bronchoconstriction begins at 6 years of age, aligning with the guidelines provided by medical authorities and the manufacturer's recommendations. Thus, the correct response regarding the age for administering montelukast for this specific condition is indeed 6 years old.